Lillian L Siu, MD, FRCPC

Dr. Siu is a senior medical oncologist at the Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at the Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026).  She is also the Clinical Lead for the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016). She currently serves on the AACR Board of Directors for a three-year term (2017-2020).

Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies.  She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution’s core vision to deliver precision cancer medicine.

Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010.  Locally, she was awarded the University of Toronto Department of Medicine Eaton Scholar Researcher in 2016.  She was the ASCO Conquer Cancer Foundation Grants Selection Committee Chair in 2009-10. She was Chairperson of the AACR Education Committee, Co-Chairperson of the Scientific Committee for the 2012 Annual Meeting and Co-Chairperson for the Clinical Trials Committee 2015-2017. Dr. Siu has published over 280 peer-reviewed manuscripts, and she is currently a scientific editor for Cancer Discovery and is on the editorial board for JAMA Oncology.

Developmental Therapeutics and Phase I Clinical Trials of Novel Agents

Dr. Siu's major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute, which aims to expedite the access and evaluation of novel anti-cancer agents.

Related Links

Oncologist. 2019 Mar 04;:
Tan T, Rheaume M, Wang L, Chow H, Spreafico A, Hansen AR, Razak ARA, Siu LL, Bedard PL
Gynecol Oncol. 2019 Feb 18;:
Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM
Cancer. 2019 Feb 15;:
Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL
Target Oncol. 2019 Feb 11;:
de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL
Target Oncol. 2019 Feb 11;:
Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP
Oncologist. 2019 Feb 06;:
Shepshelovich D, McDonald K, Spreafico A, Razak ARA, Bedard PL, Siu LL, Minasian L, Hansen AR
Int J Gynecol Cancer. 2019 Jan 18;:
Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, Karakasis K, Wang L, Dhani NC, Butler MO, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, Jurisica I, Oza AM, Lheureux S
Curr Oncol. 2018 Dec;25(6):e516-e526
Sud S, O'Callaghan C, Jonker C, Karapetis C, Price T, Tebbutt N, Shapiro J, Van Hazel G, Pavlakis N, Gibbs P, Jeffrey M, Siu L, Gill S, Wong R, Jonker D, Tu D, Goodwin R
Clin Colorectal Cancer. 2018 Nov 28;:
Wells JC, Tu D, Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Simes J, Liu G, Price TJ, Tebbutt NC, O'Callaghan CJ
Eur J Cancer. 2018 Dec 18;107:142-152
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G,...

Pages


 

Professor of Medicine, University of Toronto
Staff Physician, Division of Medical Oncology and Hematology, Princess Margaret Hospital
Director, Phase I Program and Co-Director, Robert and Maggie Bras and Family Drug Development Program, Princess Margaret Hospital